199 related articles for article (PubMed ID: 32665104)
1. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies.
Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P
Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104
[TBL] [Abstract][Full Text] [Related]
2. Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm.
Van Buskirk GA; Asotra S; Balducci C; Basu P; DiDonato G; Dorantes A; Eickhoff WM; Ghosh T; González MA; Henry T; Howard M; Kamm J; Laurenz S; MacKenzie R; Mannion R; Noonan PK; Ocheltree T; Pai U; Poska RP; Putnam ML; Raghavan RR; Ruegger C; Sánchez E; Shah VP; Shao ZJ; Somma R; Tammara V; Thombre AG; Thompson B; Timko RJ; Upadrashta S; Vaithiyalingam S;
AAPS PharmSciTech; 2014 Jun; 15(3):665-93. PubMed ID: 24578237
[TBL] [Abstract][Full Text] [Related]
3. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
[TBL] [Abstract][Full Text] [Related]
4. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
[TBL] [Abstract][Full Text] [Related]
5. Use of benchmarking in the development of biopharmaceutical products.
Giffin M; McLeish S
Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
[TBL] [Abstract][Full Text] [Related]
6. Toward biotherapeutic product real-time quality monitoring.
Guerra A; von Stosch M; Glassey J
Crit Rev Biotechnol; 2019 May; 39(3):289-305. PubMed ID: 30724608
[TBL] [Abstract][Full Text] [Related]
7. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
8. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs].
Saitoh S
Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661
[TBL] [Abstract][Full Text] [Related]
9. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
10. Scientific, statistical, practical, and regulatory considerations in design space development.
Debevec V; Srčič S; Horvat M
Drug Dev Ind Pharm; 2018 Mar; 44(3):349-364. PubMed ID: 29200316
[TBL] [Abstract][Full Text] [Related]
11. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
[TBL] [Abstract][Full Text] [Related]
12. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
13. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives.
Grangeia HB; Silva C; Simões SP; Reis MS
Eur J Pharm Biopharm; 2020 Feb; 147():19-37. PubMed ID: 31862299
[TBL] [Abstract][Full Text] [Related]
14. Understanding pharmaceutical quality by design.
Yu LX; Amidon G; Khan MA; Hoag SW; Polli J; Raju GK; Woodcock J
AAPS J; 2014 Jul; 16(4):771-83. PubMed ID: 24854893
[TBL] [Abstract][Full Text] [Related]
15. Roadmap for implementation of quality by design (QbD) for biotechnology products.
Rathore AS
Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
[TBL] [Abstract][Full Text] [Related]
16. A design space exploration for control of Critical Quality Attributes of mAb.
Bhatia H; Read E; Agarabi C; Brorson K; Lute S; Yoon S
Int J Pharm; 2016 Oct; 512(1):242-252. PubMed ID: 27575657
[TBL] [Abstract][Full Text] [Related]
17. A quality by design study applied to an industrial pharmaceutical fluid bed granulation.
Lourenço V; Lochmann D; Reich G; Menezes JC; Herdling T; Schewitz J
Eur J Pharm Biopharm; 2012 Jun; 81(2):438-47. PubMed ID: 22446063
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Maximizing Successful Drug Substance Technology Transfer Using Engineering, Shake-Down, and Wet Test Runs.
Abraham S; Bain D; Bowers J; Larivee V; Leira F; Xie J
PDA J Pharm Sci Technol; 2015; 69(5):650-7. PubMed ID: 26429113
[TBL] [Abstract][Full Text] [Related]
19. The process defines the product: what really matters in biosimilar design and production?
Vulto AG; Jaquez OA
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544
[TBL] [Abstract][Full Text] [Related]
20. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
